In a preclinical model of cachexia, it was recently shown that the potent, selective CB1/CB2 agonist WIN55,212-2 led to a significant reduction in the cachexia index and significantly prevented the cachexia-induced increase in gastric emptying [25]. This evidence concerns the gene CNR2 and Cachexia.